<code id='A9EA0750F5'></code><style id='A9EA0750F5'></style>
    • <acronym id='A9EA0750F5'></acronym>
      <center id='A9EA0750F5'><center id='A9EA0750F5'><tfoot id='A9EA0750F5'></tfoot></center><abbr id='A9EA0750F5'><dir id='A9EA0750F5'><tfoot id='A9EA0750F5'></tfoot><noframes id='A9EA0750F5'>

    • <optgroup id='A9EA0750F5'><strike id='A9EA0750F5'><sup id='A9EA0750F5'></sup></strike><code id='A9EA0750F5'></code></optgroup>
        1. <b id='A9EA0750F5'><label id='A9EA0750F5'><select id='A9EA0750F5'><dt id='A9EA0750F5'><span id='A9EA0750F5'></span></dt></select></label></b><u id='A9EA0750F5'></u>
          <i id='A9EA0750F5'><strike id='A9EA0750F5'><tt id='A9EA0750F5'><pre id='A9EA0750F5'></pre></tt></strike></i>

          Home / comprehensive / hotspot

          hotspot


          hotspot

          author:explore    Page View:812
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In